IgE und Anti-IgE bei Asthma: eine wechselvolle Geschichte

 

 Permissions and Reprints

Zusammenfassung

Es war ein langer und verschlungener Weg, der zur Entdeckung von Immunglobulin E (IgE) in den Jahren 1966 und 1967 führte. Wir befinden uns aktuell auf einem langen und verschlungenen Weg, um die immunologische Basis der klinischen Wirkung des Anti-IgE-Antikörpers Omalizumab bei Asthma zu begreifen. Möglicherweise profitieren beim Asthma (ähnlich wie bei der chronisch spontanen Urtikaria) Patienten auf unterschiedliche immunologische Art und Weise von einer Omalizumab-Therapie. Dieser Artikel gibt einen Überblick über die Historie der IgE-Entdeckung und die aktuellen Konzepte der Anti-IgE-Therapie bei Asthma.

Abstract

A long and winding road led to the discovery of immunoglobulin E (IgE) in 1966 and 1967. We are currently on a long and winding road to understand the immunologic basis of the clinical effects of the anti-IgE antibody omalizumab in asthma. It is possible that patients with asthma (as patients with chronic spontaneous urticaria) benefit in different immunologic ways from omalizumab treatment. This article reviews the history of IgE discovery and current concepts of anti-IgE therapy in asthma.

• Literatur

• 1 Johansson SG. The discovery of IgE. J Allergy Clin Immunol 2016; 137: 1671-1673
  CrossrefPubMedGoogle Scholar
• 2 Lommatzsch M, Stoll P. Novel strategies for the treatment of asthma. Allergo J Int 2016; 25: 11-17
  CrossrefPubMedGoogle Scholar
• 3 Sakula A. Sir John Floyerʼs A Treatise of the Asthma (1698). Thorax 1984; 39: 248-254
  CrossrefPubMedGoogle Scholar
• 4 Sakula A. Henry Hyde Salter (1823–71): a biographical sketch. Thorax 1985; 40: 887-888
  CrossrefPubMedGoogle Scholar
• 5 Becker RE. Remembering Sir William Osler 100 years after his death: what can we learn from his legacy?. Lancet 2014; 384: 2260-2263
  CrossrefPubMedGoogle Scholar
• 6 Ring J, Grosber M, Brockow K. et al. Anaphylaxis. Chem Immunol Allergy 2014; 100: 54-61
  PubMedGoogle Scholar
• 7 Cohen SG. Pioneers and milestones. Clemens von Pirquet, MD (1874–1929). J Allergy Clin Immunol 2002; 109: 722-724
  CrossrefPubMedGoogle Scholar
• 8 Blank U, Falcone FH, Nilsson G. The history of mast cell and basophil research – some lessons learnt from the last century. Allergy 2013; 68: 1093-1101
  PubMedGoogle Scholar
• 9 Rackemann FM. A clinical study of one hundred and fifty cases of bronchial asthma. Arch Intern Med 1918; 12: 517-552
  PubMedGoogle Scholar
• 10 Ramirez MA. Horse asthma following blood transfusion: Report of case. Journal of the American Medical Association 1919; 73: 984-985
  CrossrefPubMedGoogle Scholar
• 11 Göring HD. Die passive Übertragung der Soforttyp-Allergie im Selbstversuch durch Carl Prausnitz und Heinz Küstner – ein Meilenstein in der Allergieforschung. Akt Dermatol 2007; 33: 87-91
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Frankland AW. Carl Prausnitz: a personal memoir. J Allergy Clin Immunol 2004; 114: 700-704
  CrossrefPubMedGoogle Scholar
• 13 Prausnitz C, Küstner H. Studien über die Ueberempfindlichkeit. Centralbl Bakt I Abt Originale 1921; 86: 160-169
  PubMedGoogle Scholar
• 14 Coca AF, Grove EF. Studies in Hypersensitiveness: XIII. A Study of the Atopic Reagins. The Journal of Immunology 1925; 10: 445-464
  PubMedGoogle Scholar
• 15 Ishizaka K, Ishizaka T. Physicochemical properties of reaginic antibody. 1. Association of reaginic activity with an immunoglobulin other than gammaA- or gammaG-globulin. J Allergy 1966; 37: 169-185
  CrossrefPubMedGoogle Scholar
• 16 Ishizaka K, Ishizaka T, Hornbrook MM. Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity with gamma-E-globulin antibody. J Immunol 1966; 97: 840-853
  PubMedGoogle Scholar
• 17 Ishizaka K, Ishizaka T, Terry WD. Antigenic structure of gamma-E-globulin and reaginic antibody. J Immunol 1967; 99: 849-858
  PubMedGoogle Scholar
• 18 Johansson SG, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 1967; 13: 381-394
  PubMedGoogle Scholar
• 19 Johansson SG. Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet 1967; 2: 951-953
  PubMedGoogle Scholar
• 20 Bennich HH, Ishizaka K, Johansson SG. et al. Immunoglobulin E: a new class of human immunoglobulin. Immunology 1968; 15: 323-324
  PubMedGoogle Scholar
• 21 Gronemeyer W, Fuchs E, Bandilla K. [The “rubtest” and RAST]. Zeitschrift fur Hautkrankheiten 1979; 54: 205-212
  PubMedGoogle Scholar
• 22 Fuchs E, Gronemeyer W, Ivanoff I. [Determination of an actual antigen with the help of the inhalative antigen-pneumometric test]. Allerg Asthma (Leipz) 1957; 3: 235-238
  PubMedGoogle Scholar
• 23 Ishizaka K, Tomioka H, Ishizaka T. Mechanisms of passive sensitization. I. Presence of IgE and IgG molecules on human leukocytes. J Immunol 1970; 105: 1459-1467
  PubMedGoogle Scholar
• 24 Tomioka H, Ishizaka K. Mechanisms of passive sensitization. II. Presence of receptors for IgE on monkey mast cells. J Immunol 1971; 107: 971-978
  PubMedGoogle Scholar
• 25 Garman SC, Kinet JP, Jardetzky TS. Crystal structure of the human high-affinity IgE receptor. Cell 1998; 95: 951-961
  CrossrefPubMedGoogle Scholar
• 26 Conner ER, Saini SS. The immunoglobulin E receptor: expression and regulation. Curr Allergy Asthma Rep 2005; 5: 191-196
  CrossrefPubMedGoogle Scholar
• 27 MacGlashan Jr DW, Bochner BS, Adelman DC. et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158: 1438-1445
  PubMedGoogle Scholar
• 28 Foster B, Metcalfe DD, Prussin C. Human dendritic cell 1 and dendritic cell 2 subsets express FcepsilonRI: correlation with serum IgE and allergic asthma. J Allergy Clin Immunol 2003; 112: 1132-1138
  CrossrefPubMedGoogle Scholar
• 29 Stoll P, Bahker A, Ulrich M. et al. The dendritic cell high-affinity IgE receptor is overexpressed in both asthma and severe COPD. Clin Exp Allergy 2016; 46: 575-583
  CrossrefPubMedGoogle Scholar
• 30 Holgate S, Casale T, Wenzel S. et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115: 459-465
  CrossrefPubMedGoogle Scholar
• 31 Presta LG, Lahr SJ, Shields RL. et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2623-2632
  CrossrefPubMedGoogle Scholar
• 32 Boulet LP, Chapman KR, Cote J. et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155: 1835-1840
  CrossrefPubMedGoogle Scholar
• 33 Fahy JV, Fleming HE, Wong HH. et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155: 1828-1834
  CrossrefPubMedGoogle Scholar
• 34 Milgrom H, Fick Jr RB, Su JQ. et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999; 341: 1966-1973
  CrossrefPubMedGoogle Scholar
• 35 Busse W, Corren J, Lanier BQ. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-190
  CrossrefPubMedGoogle Scholar
• 36 Humbert M, Beasley R, Ayres J. et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-316
  CrossrefPubMedGoogle Scholar
• 37 Garcia G, Magnan A, Chiron R. et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 2013; 144: 411-419
  CrossrefPubMedGoogle Scholar
• 38 Arm JP, Bottoli I, Skerjanec A. et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 2014; 44: 1371-1385
  CrossrefPubMedGoogle Scholar
• 39 Gauvreau GM, Arm JP, Boulet LP. et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J Allergy Clin Immunol 2016; 138: 1051-1059
  CrossrefPubMedGoogle Scholar
• 40 Vorab-Veröffentlichung der Ergebnisse auf der Internetseite der Fa Novartis. https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=15687
  PubMedGoogle Scholar
• 41 Harris JM, Maciuca R, Bradley MS. et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir Res 2016; 17: 29
  CrossrefPubMedGoogle Scholar
• 42 Maurer M, Rosen K, Hsieh HJ. et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368: 924-935
  CrossrefPubMedGoogle Scholar
• 43 Voskamp AL, Gillman A, Symons K. et al. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. The journal of allergy and clinical immunology In practice 2015; 3: 192-199
  CrossrefPubMedGoogle Scholar
• 44 Burrows B, Martinez FD, Halonen M. et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320: 271-277
  CrossrefPubMedGoogle Scholar
• 45 Prussin C, Griffith DT, Boesel KM. et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003; 112: 1147-1154
  CrossrefPubMedGoogle Scholar
• 46 Lommatzsch M, Korn S, Buhl R. et al. Against all odds: anti-IgE for intrinsic asthma?. Thorax 2014; 69: 94-96
  CrossrefPubMedGoogle Scholar
• 47 Chanez P, Contin-Bordes C, Garcia G. et al. Omalizumab-induced decrease of FcxiRI expression in patients with severe allergic asthma. Respir Med 2010; 104: 1608-1617
  CrossrefPubMedGoogle Scholar
• 48 Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol 2015; 15: 471-485
  CrossrefPubMedGoogle Scholar
• 49 Schroeder JT, Bieneman AP, Xiao H. et al. TLR9- and FcepsilonRI-mediated responses oppose one another in plasmacytoid dendritic cells by down-regulating receptor expression. J Immunol 2005; 175: 5724-5731
  CrossrefPubMedGoogle Scholar
• 50 Tversky JR, Le TV, Bieneman AP. et al. Human blood dendritic cells from allergic subjects have impaired capacity to produce interferon-alpha via Toll-like receptor 9. Clin Exp Allergy 2008; 38: 781-788
  CrossrefPubMedGoogle Scholar
• 51 Ritchie AI, Farne HA, Singanayagam A. et al. Pathogenesis of Viral Infection in Exacerbations of Airway Disease. Annals of the American Thoracic Society 2015; 12 (Suppl. 02) S115-S132
  PubMedGoogle Scholar
• 52 Teach SJ, Gill MA, Togias A. et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015; 136: 1476-1485
  CrossrefPubMedGoogle Scholar
• 53 Sanjuan MA, Sagar D, Kolbeck R. Role of IgE in autoimmunity. J Allergy Clin Immunol 2016; 137: 1651-1661
  CrossrefPubMedGoogle Scholar
• 54 Kolkhir P, Church MK, Weller K. et al. Autoimmune chronic spontaneous urticaria: what we know and what we donʼt know. J Allergy Clin Immunol 2016; DOI: 10.1016/j.jaci.2016.08.050. [Epub ahead of print]
  CrossrefPubMedGoogle Scholar
• 55 Gericke J, Metz M, Ohanyan T. et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol 2017; 139: 1059-1061
  CrossrefPubMedGoogle Scholar